Patents Examined by Marsha Tsay
  • Patent number: 10988730
    Abstract: The invention relates to a lyophilisate or to a powder including i) at least one globin, a globin protomer or an extracellular hemoglobin from annelids, and ii) at least one biological material from annelids that is different from said globin, from said protomer and from said hemoglobin.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 27, 2021
    Assignee: Hemarina
    Inventor: Franck Zal
  • Patent number: 10975375
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 10975389
    Abstract: Some embodiments of the methods and compositions provided herein relate to the preparation surfactant protein-D (SP-D). Some embodiments include the expression of human SP-D in certain cell lines, and the purification of human SP-D from such cell lines. Some embodiments include the preparation of certain oligomeric forms of human SP-D.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 13, 2021
    Assignee: Airway Therapeutics, Inc.
    Inventors: Jan Susan Rosenbaum, Frederick Gyapon Quast, Matthias Kaup, Lars Stöckl
  • Patent number: 10947269
    Abstract: The invention is directed to methods of purifying a chimeric protein comprising subjecting the chimeric protein to a factor VIII-specific affinity chromatography, and subjecting the chimeric protein to an AEX chromatography; wherein the chimeric protein comprises a factor VIII protein or a fragment thereof. The chimeric protein purified by the present methods shows improved factor VIII activity.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Lily Zhu, Anxhela Kole, John Kulman, Marisol Acosta
  • Patent number: 10933173
    Abstract: A microneedle or microneedle device includes a microneedle body extending from a base to a penetrating tip formed from a silk fibroin based material, which is easy to fabricate and highly biocompatible. The microneedle device can include one or more microneedles mounted to a substrate. The silk fibroin can include active agents to be transported into or across biological barriers such as skin, tissue and cell membranes. The silk fibroin microneedles can be fully or partially biodegradable and/or bioerodible. The silk fibroin is highly stable, affords room temperature storage and is implantable. The silk fibroin structure can be modulated to control the rate of active agent delivery.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 2, 2021
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Konstantinos Tsioris, Fiorenzo G. Omenetto, Eleanor M. Pritchard
  • Patent number: 10899803
    Abstract: Sucker ring tooth (SRT) proteins called Suckerins were identified from the sucker tissue of three distantly related Decapodiformes species. These proteins assemble into silk-like beta-sheet reinforced materials. The use of suckerin proteins to produce fibres, films and tissue scaffolds is also described.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 26, 2021
    Assignees: Nanyang Technological University, Agency for Science, Technology and Researech
    Inventors: Paul Andre Guerette, Ali Gilles Tchenguise Miserez, Shawn Hoon
  • Patent number: 10899804
    Abstract: Provided is a green-yellow fluorescent protein with high pH stability (with reduced pH sensitivity). In one or more embodiments, the fluorescent protein is a fluorescent protein comprising an amino acid sequence from position 2 to 225 of the amino acid sequence of SEQ ID NO: 1, at least a mutation being introduced into the sequence, wherein the above-mentioned mutation is selected from the group consisting of F149T or S or A, L158T or S or A, H160T or S or A, Y174T or S or A, and Y192T or S or A as well as combinations of 2 to 5 thereof.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 26, 2021
    Assignee: Osaka University
    Inventors: Takeharu Nagai, Hajime Shinoda, Tomoki Matsuda, Yuanqing Ma
  • Patent number: 10894953
    Abstract: The disclosure relates to enzyme variants with improved ester synthase properties for the production of fatty acid esters. Further contemplated are recombinant host cells that express such variants, cell cultures comprising the recombinant host cells and fatty acid ester compositions produced by such recombinant host cells.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 19, 2021
    Assignee: Genomatica, Inc.
    Inventors: Andrew M. Shumaker, Bernardo M. da Costa, Kevin Holden, Louis G. Hom, Tarah S. Baron, Noah Helman
  • Patent number: 10882889
    Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 5, 2021
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: Mark Bruce, James Anthony Clarke, Andrew John Heron, Lakmal Jayasinghe, Elizabeth Jayne Wallace
  • Patent number: 10883097
    Abstract: The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 5, 2021
    Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH
    Inventors: Erhard Seifried, Jörg Schüttrumpf
  • Patent number: 10857233
    Abstract: Protease inhibitors together with protease sensitive therapeutics or diagnostics are provided, which may be ionically or covalently bound, or unbound. The protease inhibitors and/or protease sensitive moiety may be provided in monomeric, homopolymeric, heteropolymeric (for each of the protease and agent) and/or block copolymeric (combining polymers of agent and inhibitor) form. The inhibitors may be native active or e.g., protease activated. Multiple protease inhibitor peptides may be used in-frame with multiple protease cleavage signals (polymeric protease activated protease inhibitors). Combination with the protease inhibitors with the protease sensitive therapeutic enhances the intact, active molecule local-regional or targeted cell or tissue concentration, peak concentration and/or duration of the therapeutic exposure, thereby increasing its therapeutic efficacy. The protease inhibitors are particularly useful for tumor-targeted therapies and for vaccines.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 8, 2020
    Inventor: David Gordon Bermudes
  • Patent number: 10849983
    Abstract: This invention relates to an albumin-curcumin conjugate for application in cancer therapy, including albumin and curcumin.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: December 1, 2020
    Assignees: Sree Chitra Tirunal Institute for Medical Sciences and Technology, Indian Council of Medical Research
    Inventors: Lissy Kalliyana Krishnan, Christina Thomas
  • Patent number: 10851364
    Abstract: The invention relates to a method of controlling a polypeptide modification reaction, in particular but not exclusively, a method of controlling the activation of human factor VII (FVII) to produce human factor VII(a) (FVII(a)). The invention also relates to polypeptides obtainable by the polypeptide modification reaction and to pharmaceutical compositions comprising said polypeptides.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: December 1, 2020
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Lars Sejergaard, Janus Krarup
  • Patent number: 10829539
    Abstract: The present invention relates to improved methods for the recombinant production of von Willebrand factor (vWF) in a bioreactor by separating different multimeric forms of vWF with different molecular weight during fermentation.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: November 10, 2020
    Assignee: CSL Limited
    Inventors: Stefan Debus, Holger Lind
  • Patent number: 10822372
    Abstract: One subject of the present invention is the use of a combination of a polyol (i) consisting of 12 carbon atoms and of a polyol (ii) consisting of 4 to 6 carbon atoms, as protein stabilizer. Another subject of the present invention is protein compositions comprising such a combination. A final subject of the present invention is a process for preparing protein compositions using such a combination.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: November 3, 2020
    Assignee: ROQUETTE FRERES
    Inventors: Merveille Nono, Nicolas Descamps, Denis Simon, Olaf Haeusler
  • Patent number: 10822393
    Abstract: A process for manufacturing of a Factor VIII product having a ratio of FVIII:C/FVIII:Ag of at least 0.7 in the Factor VIII product by using chromatography wherein at least one chromatographic step is performed by means of employing; An affinity chromatography resin having an affinity for specifically binding of Factor VIII which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kD yeast derived Fab antibody fragment directed to the Factor VIII molecule. An anionic chromatography resin. A size exclusion resin. A Factor VIII product obtainable according to the process with a monomer content of >98% for treatment of haemophilia and avoiding formation of inhibitors.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: November 3, 2020
    Assignee: OCTAPHARMA AG
    Inventors: Stefan Winge, Marina Dadaian, Erica Johansson, Birte Fuchs
  • Patent number: 10821158
    Abstract: The present invention relates generally to polyethylene glycol (PEG) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of the hemoglobin.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 3, 2020
    Inventors: Ashok Malavalli, Gnel Mkrtchyan, Kim D. Vandegriff
  • Patent number: 10815461
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: October 27, 2020
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch
  • Patent number: 10815514
    Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides, glycosides of steviol precursors, and steviol glycoside precursors.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 27, 2020
    Assignee: Evolva SA
    Inventors: Kim Olsson, Joseph Michael Sheridan, Laura Tatjer Recorda, Christian Nyffengger, Veronique Douchin
  • Patent number: 10815293
    Abstract: A method for purifying fibrinogen includes steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1st glycine precipitation); (b) dissolving the precipitate of 1st glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2nd glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3rd glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration using a nanofilter.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: October 27, 2020
    Assignee: GREEN CROSS HOLDINGS CORPORATION
    Inventors: Jun Sic Kim, Hyo Jin Kim, Ji Yoon Park, Ju Ho Lee, Jae Woon Son, Yong Won Shin